A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP)

Desai Dhaval0 个研究点目标入组 40 人开始时间: 2021年6月11日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 招募中
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•1. Subject must be >=18 years of age, at the time of signing the informed consent. Specific for Japan; Subject must be >=20 years of age, at the time of signing the informed consent.
•2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.
•3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.
•4. DLCO 70% predicted or lower at the screening and baseline visits.
•5. Change in % predicted DLCO of <15% points during the screening period.
•6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak MET =<8).
•7. Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.
•8. Resting SpO2 >85% during 15 minutes without use of supplemental oxygen at the screening visits.
•9. Male or female
•10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•a. Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate
•contraception as described below.
•b. Female subjects: Females who have been post-menopausal* for >1 year, or females of childbearing potential** after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion,vasectomized partner, sexual abstinence***), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
•11. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
•12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.

排除标准

•1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
•2. WLL performed within 3 months prior to baseline.
•3. Requirement for WLL at screening or baseline.
•4. GM-CSF treatment within 6 months prior to baseline.
•5. Treatment with rituximab within 6 months prior to baseline.
•6. Treatment with plasmapheresis within 6 weeks prior to baseline.
•7. Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
•8. Previously randomized in this trial.
•9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
•10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g., more than 10 mg/day systemic prednisolone) immunosuppression.
•11. Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
•12. History of, or present, myeloproliferative disease or leukemia.
•13. Apparent pre-existing concurrent pulmonary fibrosis, or diagnosis of interstitial lung disease other than aPAP.
•14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise or confound assessment of the primary endpoint: including presence of pulmonary edema,or diagnosis of chronic obstructive pulmonary disease (COPD), pulmonary vasculitis, or pulmonary hypertension.
•15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
•16. Physical disability or other condition that precludes safe and adequate exercise testing.
•17. Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
•18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
•19. Any subject considered to be vulnerable on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty.

研究者

发起方

Desai Dhaval

相似试验

进行中（未招募）

1 期

A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution byinhalation.Autoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 21.1Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855

EUCTR2020-001263-85-ROSavara ApS160

已完成

不适用

Clinical trial of fluoride varnish in preventing dental caries of Sjögren’s syndrome patients

ISRCTN85164658Research Grants Council of Hong Kong120

已完成

3 期

Herbal formulation clinical trial for immune support

CTRI/2020/02/023359Botanic Healthcare Pvt Ltd

进行中（未招募）

1 期

A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation.Autoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 21.1Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855

EUCTR2020-001263-85-DESavara ApS160

已完成

不适用

A Clinical study to evaluate the efficacy and tolerability of 5-LOXIN in patients with mild osteoarthritis of knee

CTRI/2020/10/028725Ju Yeong NS Co Ltd100